Soiffer RJ, et al. - A prospective, double-blind phase III trial was conducted to determine the effect of ATLG (anti–T-lymphocyte globulin) on chronic graft-versus-host disease (cGVHD)-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Here, the incorporation of ATLG seemed not enhancing moderate-severe cGVHD-free survival. With ATLG, moderate-severe cGVHD was significantly lower, however, PFS and OS were also lower. To understand the appropriate role for ATLG in hematopoietic cell transplantation, additional analyses seemed required.